Accéder au contenu
Merck
Toutes les photos(3)

Documents

C4397

Sigma-Aldrich

Chlorzoxazone

Synonyme(s) :

5-Chloro-2(3H)-benzoxazolone, 5-Chloro-2-hydroxybenzoxazole

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(3)

About This Item

Formule empirique (notation de Hill):
C7H4ClNO2
Numéro CAS:
95-25-0
Poids moléculaire :
169.57
Numéro CE :
202-403-9
Numéro MDL:
MFCD00005717
Code UNSPSC :
12352200
ID de substance PubChem :
24277702
Nomenclature NACRES :
NA.77

Pureté

≥98% (TLC)

Forme

powder

Couleur

white to off-white

Pf

191-192 °C (lit.)

Solubilité

DMSO: 50 mg/mL, clear

Auteur

Johnson & Johnson

Température de stockage

room temp

Chaîne SMILES 

Clc1ccc2OC(=O)Nc2c1

InChI

1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)

Clé InChI

TZFWDZFKRBELIQ-UHFFFAOYSA-N

Informations sur le gène

human ... KCNN4(3783)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Chlorzoxazone may be used:
  • as a calcium-activated potassium (KCa) channel activator in patch-clamp electrophysiology to test its effect on dendritic hyperexcitability
  • as a substrate for cytochrome P450 2E1 (CYP2E1) enzyme in cultured human hepatocytes
  • as a benzimidazolone compound to test its effect on epithelial sodium (Na+) transport

Actions biochimiques/physiologiques

Chlorzoxazone inhibits the multisynaptic reflex arcs primarily in the spinal cord and brain subcortical areas. It is an activator of calcium activated potassium channels and may contribute to the aortic artery relaxation in mice. Chlorzoxazone also activates the calcium-activated potassium (KCa) channel and small conductance calcium-activated potassium channels (SK). It is metabolized by cytochrome P450 2E1 (CYP2E1) and serves as a probe for monitoring this enzyme function.
Chlorzoxazone is a skeletal muscle relaxant.

Caractéristiques et avantages

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H315,H319,H335

Classification des risques

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 6

1 of 6

Tolbutamide analytical standard

Supelco

T0891

Tolbutamide

Bupropion Hydrochloride Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1730

Bupropion Hydrochloride

Sulfaphenazole ≥98%

Sigma-Aldrich

S0758

Sulfaphenazole

Coumarin ≥99% (HPLC)

Sigma-Aldrich

C4261

Coumarin

Umbelliferone 99%

Sigma-Aldrich

H24003

Umbelliferone

L-Penicillamine 99%

Sigma-Aldrich

196312

L-Penicillamine

Cyrus Ghobadi et al.
Clinical pharmacokinetics, 50(12), 809-822 (2011-11-18)
The maintenance dose of a drug is dependent on drug clearance, and thus any biochemical and physiological changes in obesity that affect parameters such as cardiac output, renal function, expression of drug-metabolizing enzymes and protein binding may result in altered
F Woodward Hopf et al.
Biological psychiatry, 69(7), 618-624 (2011-01-05)
Alcoholism imposes a tremendous social and economic burden. There are relatively few pharmacological treatments for alcoholism, with only moderate efficacy, and there is considerable interest in identifying additional therapeutic options. Alcohol exposure alters SK-type potassium channel (SK) function in limbic
Yong-Long Han et al.
Journal of ethnopharmacology, 139(1), 104-109 (2011-11-15)
Herba Erigerontis injection (HEI), one of the most popular herbal prescription in China, is made from the aqueous extracts of Erigeron breviscapus whole plant. Now HEI is widely used for the treatment of cardiovascular diseases and cerebrovascular diseases such as
Karina Alviña et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(21), 7249-7257 (2010-05-28)
Episodic ataxia type-2 (EA2) is an inherited movement disorder caused by mutations in the gene encoding the Ca(v)2.1alpha1 subunit of the P/Q-type voltage-gated calcium channel that result in an overall reduction in the P/Q-type calcium current. A consequence of these
Karina Alviña et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(21), 7258-7268 (2010-05-28)
Episodic ataxia type 2 (EA2) is a hereditary cerebellar ataxia associated with mutations in the P/Q-type voltage-gated calcium (Ca(2+)) channels. Therapeutic approaches for treatment of EA2 are very limited. Presently, the potassium (K(+)) channel blocker 4-aminopyridine (4-AP) constitutes the most
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique